You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

Claims for Patent: 9,352,051


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 9,352,051
Title:Kits containing DLL3 antibody drug conjugates
Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
Inventor(s): Stull; Robert A. (Alameda, CA), Saunders; Laura (San Francisco, CA), Dylla; Scott J. (Emerald Hills, CA), Foord; Orit (Foster City, CA), Liu; David (San Francisco, CA), Torgov; Michael (Los Angeles, CA), Shao; Hui (Foster City, CA)
Assignee: Stemcentrx, Inc. (South San Francisco, CA)
Application Number:15/005,962
Patent Claims:1. A kit for treating cancer comprising: (a) one or more containers containing a composition comprising an antibody drug conjugate of the formula M-[L-D]n, or a pharmaceutically acceptable salt thereof, wherein: M comprises an anti-DLL3 antibody, wherein the anti-DLL3 antibody is an internalizing antibody; L comprises a linker; D comprises a pyrrolobenzodiazepine (PBD); and n is an integer from 1 to 20; and (b) a label or package insert on or associated with the one or more containers indicating the composition is for treating cancer.

2. The kit of claim 1, wherein the one or more containers is an intravenous solution bag, a vial, a bottle, or a syringe.

3. The kit of claim 1, wherein the composition is provided as a lyophilized powder.

4. The kit of claim 3, wherein the label or package insert indicate reconstitution of the lyophilized powder in sterile water or buffered saline.

5. The kit of claim 3, wherein the lyophilized powder comprises one or more substances to inhibit protein aggregation.

6. The kit of claim 5, wherein the one or more substances to inhibit protein aggregation is sucrose.

7. The kit of claim 1, wherein the anti-DLL3 antibody specifically binds to an epitope within the DSL domain of a DLL3 protein set forth as SEQ ID NO: 3 or 4.

8. The kit of claim 1, wherein the anti-DLL3 antibody specifically binds to an epitope comprising amino acids G203, R205 and P206 (SEQ ID NO: 10).

9. The kit of claim 1, wherein the anti-DLL3 antibody is a chimeric antibody, a human antibody, a CDR-grafted antibody, or a humanized antibody.

10. The kit of claim 1, wherein the anti-DLL3 antibody competes for binding to a human DLL3 protein with an antibody comprising a light chain variable region set forth as SEQ ID NO: 84 and a heavy chain variable region set forth as SEQ ID NO: 85.

11. The kit of claim 1, wherein the anti-DLL3 antibody comprises: (a) residues 24-34 of SEQ ID NO: 84 for CDR-L1, residues 50-56 of SEQ ID NO: 84 for CDR-L2, residues 89-97 of SEQ ID NO: 84 for CDR-L3, residues 31-35 of SEQ ID NO: 85 for CDR-H1, residues 50-65 of SEQ ID NO: 85 for CDR-H2 and residues 95-102 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to Kabat; or (b) a light chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 212 and a heavy chain variable region comprising an amino acid sequence set forth as SEQ ID NO: 213.

12. The kit of claim 1 wherein the antibody drug conjugate comprises the structure: ##STR00036## wherein: CBA is a cell binding agent, which comprises the anti-DLL3 antibody M; and A, L.sup.1, and L.sup.2 are components of the linker L wherein: A is a connecting group connecting L.sup.1 to the cell binding agent (CBA); L.sup.1 is optionally a cleavable linker; L.sup.2 is a covalent bond or together with the --OC(.dbd.O)-- group forms a self-immolative linker; and wherein the linker L is attached to the pyrrolobenzodiazepine (PBD) at the position of the asterisk (*).

13. The kit of claim 12, wherein L.sup.1 comprises a cleavable linker and the cleavable linker comprises a dipeptide.

14. The kit of claim 13, wherein the dipeptide is Phe-Lys, Val-Ala, Val-Lys, Ala-Lys, Val-Cit, Phe-Cit, Leu-Cit, Ile-Cit, Phe-Arg, or Trp-Cit.

15. The kit of claim 14, wherein the dipeptide is Val-Ala.

16. The kit of claim 12, wherein the moiety: ##STR00037## comprises the structure: ##STR00038## wherein the wavy line indicates the point of attachment of the structure directly to A or to a remaining portion of L1 that is further connected to A and the (*) indicates the point of attachment to the PBD.

17. The kit of claim 1, wherein the pyrrolobenzodiazepine (PBD) comprises the formula AC: ##STR00039## wherein: the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond; R.sup.2 is selected from H, OH, .dbd.O, .dbd.CH.sub.2, CN, R, OR, .dbd.CH--R.sup.D, .dbd.C(R.sup.D).sub.2, O--SO.sub.2--R, CO.sub.2R, COR, and halo, where R.sup.D is selected from R, CO.sub.2R, COR, CHO, CO.sub.2H, and halo; R.sup.6 and R.sup.9 are each independently selected from H, R, OH, OR, SH, SR, NH.sub.2, NHR, NRR', NO.sub.2, Me.sub.3Sn and halo; R.sup.7 is selected from H, R, OH, OR, SH, SR, NH.sub.2, NHR, NRR', NO.sub.2, Me.sub.3Sn and halo; R.sup.10 is the linker L connected to the anti-DLL3 antibody; Q is selected from O, S and NH; R.sup.11 is either H, or R or, where Q is O, SO.sub.3M, where M is a metal cation; R and R' are each independently selected from optionally substituted C.sub.1-12 alkyl, C.sub.3-20 heterocyclyl and C.sub.5-20 aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; X is selected from O, S, and N(H); R.sup.2'', R.sup.6'', R.sup.7'', R.sup.9'', and X'' are as defined according to R.sup.2, R.sup.6, R.sup.7, R.sup.9, and X, respectively; and R'' is a C.sub.3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted.

18. The kit of claim 17, wherein R.sup.2 is R, wherein R is a C.sub.5-20 aryl group.

19. The kit of claim 17, wherein R.sup.6 and R.sup.9 are H.

20. The kit of claim 17, wherein R.sup.7 is OR.

21. The kit of claim 20, wherein R is a C.sub.1 alkyl.

22. The kit of claim 17, wherein Q is O.

23. The kit of claim 22, wherein R.sup.11 is H.

24. The kit of claim 17, wherein X and X'' are O.

25. The kit of claim 1, wherein the label or package insert indicate that the composition is for treating lung cancer.

26. The kit of claim 25, wherein the label or package insert indicate that the composition is for treating small cell lung cancer.

27. The kit of claim 1, wherein the label or package insert indicate that the composition is for treating large cell neuroendocrine carcinoma.

28. The kit of claim 1, wherein the label or package insert indicate that the composition is for treating thyroid cancer.

29. The kit of claim 1, wherein the label or package insert indicate that that composition is for treating prostate cancer.

30. A kit for treating cancer comprising: (a) one or more containers containing a composition comprising a lyophilized antibody drug conjugate of the formula M-[L-D]n, or a pharmaceutically acceptable salt thereof, wherein: M comprises an anti-DLL3 antibody comprising residues 24-34 of SEQ ID NO: 84 for CDR-L1, residues 50-56 of SEQ ID NO: 84 for CDR-L2, residues 89-97 of SEQ ID NO: 84 for CDR-L3, residues 31-35 of SEQ ID NO: 85 for CDR-H1, residues 50-65 of SEQ ID NO: 85 for CDR-H2 and residues 95-102 of SEQ ID NO: 85 for CDR-H3, wherein the residues are numbered according to Kabat, and wherein the anti-DLL3 antibody is an internalizing antibody; L comprises a linker; D comprises a pyrrolobenzodiazepine (PBD) comprising the formula AC: ##STR00040## wherein: the dotted lines indicate the optional presence of a double bond, and wherein only one of the dotted lines in a given ring can be a double bond; R.sup.2 is selected from H, OH, .dbd.O, .dbd.CH.sub.2, CN, R, OR, .dbd.CH--R.sup.D, .dbd.C(R.sup.D).sub.2, O--SO.sub.2--R, CO.sub.2R, COR, and halo, where R.sup.D is selected from R, CO.sub.2R, COR, CHO, CO.sub.2H, and halo; R.sup.6 and R.sup.9 are each independently selected from H, R, OH, OR, SH, SR, NH.sub.2, NHR, NRR', NO.sub.2, Me.sub.3Sn and halo; R.sup.7 is selected from H, R, OH, OR, SH, SR, NH.sub.2, NHR, NRR', NO.sub.2, Me.sub.3Sn and halo; R.sup.10 is the linker L connected to the anti-DLL3 antibody; Q is selected from O, S and NH; R.sup.11 is either H, or R or, where Q is O, SO.sub.3M, where M is a metal cation; R and R' are each independently selected from optionally substituted C.sub.1-12 alkyl, C.sub.3-20 heterocyclyl and C.sub.5-20 aryl groups, and optionally in relation to the group NRR', R and R' together with the nitrogen atom to which they are attached form an optionally substituted 4-, 5-, 6- or 7-membered heterocyclic ring; X is selected from O, S, and N(H); R.sup.2'', R.sup.6'', R.sup.7'', R.sup.9'', and X'' are as defined according to R.sup.2, R.sup.6, R.sup.7, R.sup.9, and X, respectively; and R'' is a C.sub.3-12 alkylene group, which comprises a chain optionally interrupted by one or more heteroatoms, one or more rings, or both one or more heteroatoms and one or more rings, wherein the optional one or more rings are optionally substituted; and n is an integer from 1 to 20; and (b) a label or package insert on or associated with the one or more containers indicating the composition is for treating cancer.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.